IRIDEX (NASDAQ:IRIX) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of IRIDEX (NASDAQ:IRIX) in a research report report published on Wednesday morning. The brokerage issued a hold rating on the medical equipment provider’s stock.

IRIDEX Trading Up 4.0 %

Shares of NASDAQ IRIX opened at $1.03 on Wednesday. IRIDEX has a 1-year low of $0.78 and a 1-year high of $3.65. The business has a fifty day moving average price of $1.33 and a 200 day moving average price of $1.56. The stock has a market capitalization of $17.29 million, a P/E ratio of -1.54 and a beta of 0.94. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.54 and a quick ratio of 0.85.

IRIDEX (NASDAQ:IRIX) last released its quarterly earnings results on Thursday, March 27th. The medical equipment provider reported ($0.05) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.05). The business had revenue of $12.70 million for the quarter, compared to analysts’ expectations of $12.80 million. IRIDEX had a negative net margin of 22.79% and a negative return on equity of 192.95%.

About IRIDEX

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.